DVAX
Dynavax Technologies Corporation
Set alert
- YTD
- +0.78%
- 1 year
- +17.42%
- Open
- 15.50
- Prev close
- 15.50
- Mkt cap
- 1.82B
- Vol
- 5.66M
- Avg vol
- 2.40M
- EPS
- -0.37
- P/E
- 39.74
- Div yield
- 0.00%
More statistics
- Low
- 15.50
- High
- 15.50
- Beta
- 0.93
- Inst. own
- 101.55%
- Dividend
- 0.00
Key statistics
- Market cap
- 1.82B
- Enterprise value
- 1.95B
- Trailing P/E
- 39.74
- PEG ratio
- -0.07
- Price / sales
- 9.56
- Price / book
- 3.40
- Beta
- 0.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 23.99%
- Total cash
- 0
- Total debt
- 2
- Return on equity
- 8.88%
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 19, 2026 | Dec 30, 2025 | 0.08135 | 0.05 | -0.03 | -38.54% |
| Nov 5, 2025 | Sep 30, 2025 | 0.14 | 0.21 | +0.07 | +50.00% |
| Aug 7, 2025 | Jun 30, 2025 | 0.12 | 0.14 | +0.02 | +16.67% |
| May 6, 2025 | Mar 31, 2025 | 0.03 | -0.77 | -0.80 | -2,666.67% |
| Feb 20, 2025 | Dec 31, 2024 | 0.05 | 0.05 | 0.00 | 0.00% |
| Nov 7, 2024 | Sep 30, 2024 | 0.11 | 0.12 | +0.01 | +9.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 24, 2025 | William Blair | down | Outperform | Market Perform |
| Aug 22, 2025 | JMP Securities | reit | Market Outperform | Market Outperform |
| Aug 8, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
| May 7, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
| Apr 17, 2025 | Goldman Sachs | main | Sell | Sell |
| Feb 21, 2025 | Citizens Capital Markets | main | Market Outperform | Market Outperform |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- US
- Employees
- 405
- Website
- dynavax.com
News
- Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
- Blair William & Co. IL Sells 51,038 Shares of Dynavax Technologies Corporation $DVAX
- 35,615 Shares in Dynavax Technologies Corporation $DVAX Acquired by AXQ Capital LP
- Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
- OneSpaWorld Holdings Will Replace Dynavax Technologies In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On February 10,2026
- AlphaQuest LLC Boosts Stock Position in Dynavax Technologies Corporation $DVAX
- Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
- Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Average Rating of “Hold” from Brokerages
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—DVAX, FONR, DBRG, and ONTF
- Dynavax Technologies Corporation $DVAX Shares Sold by Chicago Capital LLC
Your note
Sign in to keep a note on DVAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANO FRANCIS R. PH.D. | Director | Stock Award(Grant) | Jun 10, 2025 | 42,663 |
| DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 21, 2025 | 0 |
| KISNER DANIEL L | Director | Stock Award(Grant) | Jun 10, 2025 | 23,329 |
| MACDONALD KELLY | Chief Financial Officer | Stock Award(Grant) | Feb 9, 2026 | 0 |
| METZINGER JOSEPH ANTHONY | Officer | Conversion of Exercise of derivative security | Dec 22, 2025 | 7,129 |
| MYERS SCOTT DUNSETH | Director | Purchase | Aug 21, 2025 | 35,004 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.84% | 16,249,235 | 251.86M | Sep 29, 2025 |
| Deep Track Capital, Lp | 13.39% | 15,726,349 | 243.76M | Sep 29, 2025 |
| Vanguard Group Inc | 6.84% | 8,027,448 | 124.43M | Dec 30, 2025 |
| State Street Corporation | 5.35% | 6,285,477 | 97.42M | Sep 29, 2025 |
| Millennium Management Llc | 3.86% | 4,528,415 | 70.19M | Sep 29, 2025 |
| Dimensional Fund Advisors LP | 3.04% | 3,567,252 | 55.29M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.13% | 6,022,500 | 93.35M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.33% | 3,905,943 | 60.54M | Sep 29, 2025 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.60% | 3,053,393 | 47.33M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 2,532,576 | 39.25M | Dec 30, 2025 |
| GLENMEDE FUND INC-Small Cap Equity Portfolio | 0.96% | 1,121,468 | 17.38M | Oct 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.91% | 1,068,175 | 16.56M | Sep 29, 2025 |